We are live on ! Find out more
PSC

Patient Square Capital Portfolio holdings

AUM $564M
1-Year Est. Return 261.3%
This Fund
S&P 500
This Quarter Est. Return
+6.83%
1 Year Est. Return
+261.3%
3 Year Est. Return
+328.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
+$51.9M
Cap. Flow
+$54.4M
Cap. Flow %
23.19%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
LQDA icon
Liquidia Corp
LQDA
+$99.9M

Top Sells

Rank Stock Value
1
EAR
Eargo, Inc. Common Stock
EAR
+$41M
2
ROIV icon
Roivant Sciences
ROIV
+$4.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
1
Roivant Sciences
ROIV
$24.5B
$129M 54.89%
12,228,465
-411,455
-3% -$4.44M
LQDA icon
2
Liquidia Corp
LQDA
$7.73B
$106M 45.11%
+7,182,532
New +$99.9M
EAR
3
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-15,821,299
Closed -$41M

Similar funds

TCP
ThornTree Capital Partners Boston, Massachusetts $564M AUM 36.37% 1-Year Est. Return
AHSW
Adventist Health System West Roseville, California $564M AUM 17.1% 1-Year Est. Return
KF
KKM Financial Chicago, Illinois $563M AUM 28.2% 1-Year Est. Return
KBG
Kahn Brothers Group New York $564M AUM 25.3% 1-Year Est. Return
AAS
Asset Allocation Strategies Farmington, Michigan $563M AUM 15.65% 1-Year Est. Return
LC
Lavaca Capital Houston, Texas $564M AUM 4.6% 1-Year Est. Return
AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return
OC
Opal Capital Boca Raton, Florida $565M AUM

Patient Square Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Patient Square Capital held 3 positions worth $235M, up 28% from $183M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Patient Square Capital deployed $54.4M of net new capital in Q1 2024, opening 1 new position. Its largest new stake was Liquidia Corp: 7,182,532 shares worth $106M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Roivant Sciences, an estimated $4.44M trimmed.

  • Patient Square Capital's largest Q1 2024 buy was Liquidia Corp: 7,182,532 shares worth $106M.
  • Patient Square Capital's biggest Q1 2024 reduction was Roivant Sciences, cutting an estimated $4.44M.
  • Patient Square Capital fully exited Eargo, Inc. Common Stock in Q1 2024, selling an estimated $41M.
  • Patient Square Capital's ten largest holdings make up 100% of its $235M portfolio in Q1 2024.
  • Patient Square Capital opened 1 new position and closed 1 in Q1 2024.
  • Patient Square Capital's portfolio value rose 28% quarter-over-quarter to $235M.

Based on Patient Square Capital's 13F filing for Q1 2024, filed 14 May 2024.